Naaman Tammuz

שתפו כדי שכל אזרח ישראלי ידע לאן הולכים עכשיו 5 מיליארד ש״ח שהממשלה הזאת בוזזת מאיתנו בשעת מלחמה: 1. 1.7 מיליארד ש"ח לישיבות חרדיות שתלמידיהן לא מתגייסים 2. 250 מיליון ש"ח ל"תלושי דרעי" =כספים שמגיעים ברובם למשפחות חרדיות שבוחרות לא לעבוד, ומחזקים אי יציאה לשוק העבודה ותלות בעסקנים. 3. 49 מיליון ש"ח ל"מניעת נשירה ממוסדות חרדיים". נשירה = תלמידים שעוזבים את הישיבה ומתגייסים. כן, אתם מבינים נכון, ממשלת ישראל משלמת עכשיו מיליונים מכספכם לטובת קמפיינים שמעודדים תלמידים חרדים להמשיך להשתמט ולא חלילה לשרת בצה"ל. 4. 77 מיליון ש"ח ל"תמיכה בתרבות חרדית" (ואם לא ברור לכם מה זה ולמה צריך את זה עכשיו בזמן מלחמה, אתם צודקים). 5. 200 מיליון ש"ח תוספת לתלמודי תורה חרדיים שלא מלמדים ליבה ומחנכים דור חדש ל"נמות ולא נתגייס". זה רק חלק קטן מהדוגמאות. אם זה מתאים לכם, אל תעשו דבר. אבל אם אתם לא אוהבים שבוזזים אתכם, שתפו את הפוסט הזה, כדי שכל עם ישראל ידע את מה שהממשלה מתאמצת כל כך להסתיר.

$105 million for the next frontier of Alzheimer’s treatment - and it’s not another monoclonal antibody. Cognito Therapeutics announced the close of an oversubscribed $105 million Series C, bringing its total funding to $233 million. The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with strong participation from new investors including New Vintage Partners, Apollo Health Ventures, and Benvolio Group. At the center of this momentum is Spectris, a physician-prescribed, at-home wearable neurostimulation device that looks like sleek sunglasses connected to over-ear headphones. Patients simply wear it for one hour per day while it delivers precisely synchronized 40 Hz gamma-frequency light and sound stimulation. By non-invasively restoring disrupted gamma brain rhythms that decline early in Alzheimer’s, the therapy drives meaningful downstream effects. It reduces amyloid and tau pathology, helps preserve brain structure such as the corpus callosum, and meaningfully slows neurodegeneration. In the completed OVERTURE Phase 2 randomized, sham-controlled study and its open-label extension, patients using Spectris experienced a 77 percent reduction in the decline of daily function on the ADCS-ADL scale, a 76 percent reduction in cognitive decline on the MMSE, a 69 percent reduction on the integrated Alzheimer’s Disease Rating Scale, and a 56 percent lower Alzheimer’s Dependence Score. These benefits were sustained through the 18-month open-label extension, all with excellent safety and no serious device-related adverse events. The device carries FDA Breakthrough Device Designation for cognitive and functional symptoms in Alzheimer’s. A non-pharmacological, disease-modifying therapy that patients can use comfortably at home, with the potential for fewer side effects and far broader accessibility than today’s anti-amyloid infusions. It also opens the door for future expansion into other neurodegenerative diseases. #AlzheimersDisease #Neurotechnology #Neurodegeneration #DigitalHealth #Biopharma #Neuroscience #BreakthroughDevice #Longevity

underscores should be called lowphens, thanks for coming to my ted talk

@nimivashi15 Out of curiosity, why do you think this requires a consortium, as opposed to e.g. each company independently transferring and licensing the data to some data marketplace?

Biotech companies don’t share data to train models but the ones that can’t raise more funding and are closing down can. It requires a consortium. I am surprised nobody is building one.

Fun talking today about data sovereignty within clinical trials in LatAm with @Farma_con. Seems like LatAm has a lot of interest in expanding what they do in clinical trials and does seem AI could play a big part!

Bitfount is coming to the ARVO 2025 annual meeting in Salt Lake City, Utah, next month from 4-7th of May 2025. 📍Booth 2036

Interesting time yesterday speaking about the pros and cons of federated analytics yesterday with EOSC-ENTRUST... my view: Contracting: easier; Regulatory: easier, Governance: depends; Risks: different; Technical complexity: different. 🧵1/6

David Friend joins Bitfount as Head of Business Development. Read the full announcement here: bitfount.com/post/david-fri…

Bitfount x @Altris_AI at Euretina 2024. 📍Booth A8 Catch our demo of Altris AI's Geographic Atrophy segmentation model in action and speak to our team of AI and privacy specialists about accelerating patient enrolment for your AMD trials with on-prem AI.

Catch Bitfount at @EURETINA 2024 Congress in Barcelona starting today till the 22nd of September. 📍Booth A8

Proud to have been involved with this exciting project and even prouder to be enabling AI-based trial pre-screening without any data transfer via @bitfount! Drop us a line 📞

Artificial intelligence to facilitate clinical trial recruitment in age-related macular degeneration ow.ly/q6A250SmnfJ @dominicwllmsn @pearsekeane @FaresAntaki @sktywagner @markachia @sktywagner @RobbertStruyven @ntammuz @blaisethom @reena_cho #ophthalmology

UK researchers have developed a new #AI system that could significantly reduce the time and cost required to recruit clinical trial patients for an advanced form of age-related vision loss htworld.co.uk/news/ai/ai-mod… #clinicaltrials #artificialintelligence #visionloss

Sign up for free today and start using RETFound! RETFound is the world's first retinal foundation model, created by a cross-institutional team led by @Moorfields and @ucl, and trained on 1.6 million retinal images.

Thanks for spreading the word @NEIDirector 😀

From @UCLEye @Moorfields: an AI algorithm to identify potential clinical trial candidates for geographic atrophy studies from EHR data & OCT images. @pearsekeane @dominicwllmsn @FaresAntaki @markchia @sktywagner @reena_cho @INSIGHTeyehub @AAOJournal: bit.ly/4cHLPIM

Research from @dominicwllmsn @pearsekeane and team at @Moorfields @UCLeye in collaboration with @bitfount @UniOfSurrey @EyeResearchAus @UniMelbMDHS - using data from @INSIGHTeyehub, the world's largest #ophthalmology bio-resource

🚀 We are proud to have been recognised as a contributor to DARE UK's latest AI Risk Evaluation Report. This report analysed various privacy-preserving techniques in AI and their applications in healthcare data. Read the full report: zenodo.org/records/110456…

The number of AI models released to the public has increased exponentially over the last few years, but there's a catch: a recent study by Aaron Y. lee MD et al. (@aaronylee) concluded that 6 out of 7 models are not actually ready for real-world use. AI model validation. 🧵

“Clinical trials can save more lives, and faster, with AI” freethink.com/health/clinica…